retatrutide trial update october 2025 approval: FDA status, clinical results, and when it could be available Retatrutide Phase 3: 60% Achieved

Discover how consumer health brands can better support the evolving needs of GLP-1 consumers and why targeted nutrition solutions are becoming increasingly important

Expert care, personalized plans, and GLP-1 medications delivered to Smyrna, Tennessee

Glucagon-like-peptide-1 receptor agonists (GLP-1s) have transformed weight management and treatment of chronic disease

The work of Lebrun et al now adds an important piece to this puzzle by describing a critical and previously unrecognized role for the gut-derived hormone glucagon-like-peptide 1 (GLP-1) in the regulation of intestinal inflammation

GLP3-R is a synthetic peptide studied in research for triple receptor activity involving GLP-1, GIP, and glucagon pathways, with focus on signaling and metabolic regulation.